Ecolab Inc reported Q1 2024 earnings surpassing consensus estimates for both EPS and revenue, signaling robust demand in its service segments. The positive results reflect stability in the industrial water treatment and hygiene sector, supporting downstream food and pharmaceutical operations. Consistent outperformance strengthens Ecolab's competitive positioning, though detailed forward guidance remains absent from this initial release.
34 articles
Ecolab Inc reported Q1 2024 earnings exceeding EPS and revenue expectations, posting CHF1.10 per share and CHF3.07 billion in revenue. The next earnings release is scheduled for November 3, 2026.
Ecolab shares traded above $280 following strong Q2 2026 earnings with 9.7% revenue growth and EPS beating estimates, supported by positive Q3 guidance and analyst upgrades.
Ecolab raised full-year adjusted EPS guidance following strong Q2 FY2026 earnings, pushing shares up 4.2%. Despite positive momentum, valuation debates persist regarding its high P/E ratio versus indu
Ecolab Inc. reported strong Q2 2026 earnings with $2.09 adjusted EPS and $4.42 billion in revenue, beating consensus estimates. Optimistic Q3 guidance and its core water treatment business continue to
Erste Group Bank increased Ecolab's FY2027 EPS estimate to $9.36 following strong quarterly results exceeding expectations. Analysts maintain a "Moderate Buy" rating with a price target of $327.56.
Ecolab reported steady second-quarter results with strong share momentum, affirming its dividend despite a P/E ratio significantly higher than peers. Investors are weighing if the premium valuation is
Ecolab Inc. announced a 5-for-1 stock split effective August 17, 2026, accompanied by new analyst price targets and recommendations. The report covers current stock prices and general market data for
Ecolab Inc reported an 11% rise in adjusted EPS and 5% organic sales growth, with analysts suggesting the stock is 14% undervalued despite a high P/E ratio.
Ecolab Inc reported strong Q2 2026 results with 11% adjusted EPS growth and raised its full-year outlook. Global High-Tech sales surged 29% driven by data center and AI infrastructure demand, supporti
Ecolab Inc. reported 5% organic sales growth for Q2 2026 and raised full-year EPS guidance to $8.05–$8.25. Strong performance in Life Sciences and High-Tech segments offset rising commodity costs.
Ecolab Inc reported strong Q2 2026 results with 11% adjusted EPS growth, raising its full-year EPS outlook to $8.05-$8.25. The company implemented a global energy surcharge to offset rising commodity
Ecolab Inc. reported Q2 2026 adjusted EPS of $2.09 against estimates, with revenue rising 10% to $4.42 billion driven by its Global Water segment, while issuing FY 2026 EPS guidance of $8.05–$8.25.
Ecolab Inc. is set to release Q2 results with analysts projecting earnings and revenue improvements. Investors will focus on pricing gains and margin expansion amid easing commodity headwinds.
Ecolab Inc releases Q2 2026 results on July 28, expecting organic growth despite margin pressures from elevated commodity costs. Investors will monitor management's outlook on margin recovery and the
Ecolab Inc. is expected to report Q2 earnings of $2.08 per share, up 10.1% year-over-year, with revenues projected at $4.4 billion. Wall Street analysts have recently revised consensus EPS estimates d
Ecolab Inc reported Q4 2023 earnings beating consensus with $1.55 EPS and $3.94 billion revenue. The results reflect strong demand for its water, hygiene, and infection prevention solutions.
Ecolab Inc reported strong Q1 2026 earnings with $4.07 billion revenue and $1.70 EPS, beating consensus. The company reaffirmed full-year adjusted diluted EPS growth guidance of 12%-15%, citing solid
Ecolab shares trade near 52-week highs following Q1 2026 earnings that exceeded analyst expectations with $3.9 billion revenue. Strong growth in its water management solutions segment supports the com
Ecolab reported strong Q1 2026 earnings with double-digit adjusted EPS growth of 13% and net sales reaching $4.07 billion. The company reaffirmed its full-year outlook and expects to close its $4.75 b
Ecolab Inc. is recommended for retention following strong first-quarter 2026 results driven by its digital platform and R&D-backed portfolio. However, investors should monitor potential risks from raw
Ecolab Inc. has scheduled a live webcast for July 28, 2026, to discuss second quarter 2026 financial results, with a press release expected prior to market open.
Ecolab Inc. submitted an SEC Form 144 filing detailing a proposed sale of 1,004 shares by a non-employee director, with an aggregate market value of $255,247.
Ecolab Inc. reported strong Q1 2025 earnings with increased sales, confirming its full-year outlook. Investor optimism drives stock levels due to exposure to structural themes like water scarcity and
Ecolab Inc. reported strong Q1 2025 results with resilient demand for its water and hygiene solutions. The company reaffirmed its full-year outlook as investor optimism grows around water scarcity and
Ecolab reported strong first-quarter 2026 results with higher sales and improved profitability in its cleaning and industrial water businesses. The company reaffirmed its full-year earnings growth out
Ecolab reported Q1 2026 revenue of $4.07 billion, surpassing analyst estimates with 10% year-over-year growth. The performance was driven by high demand for water, hygiene, and energy solutions in ins
Ecolab Inc reported Q1 2026 EPS of $1.70, meeting estimates, with revenue rising 10% to $4.07 billion. Q2 EPS guidance was set at $2.02-$2.12, supported by strong water treatment and hygiene solutions
Ecolab reported Q1 revenue of $4.07 billion and net income of $432.6 million, while opening its first Asian Bioprocessing Applications Lab in Korea. These moves strengthen its Life Sciences segment de
Ecolab Inc. reported strong first-quarter 2026 financial results with increased sales and net income, surpassing prior year figures. Analyst upgrades to a Moderate Buy rating boosted investor sentimen
Ecolab reported Q1 2026 revenue of US$4.066 billion and net income of US$432.6 million, alongside opening its first Asian Bioprocessing Applications Lab in Dongtan, Korea. This expansion supports the
ChemBrief